News & Events
-
September 27, 2022
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.
-
September 8, 2022
C-Path’s Kristen Swingle Named President
Swingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path... -
April 25, 2016
New Database for Sharing MS Clinical Trial Data
April 25, 2016 Sharing Clinical Trial Data for Multiple Sclerosis Standardized and Pooled Data Available for Secondary Research New York and Tucson – April 25, 2016. A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.... - June 4, 2014
-
January 3, 2014
An Expanded Role for Patients in Clinical Trial Design – Podcast
A discussion with Dr. Anne Rowzee of the Center for Drug Evaluation and Research, US FDA about patient input into the design of studies of medicines for multiple sclerosis.–Therapeutic Innovation & Regulatory Science Podcast Series – November 2013 Download MP3